Coya Therapeutics
Develops Treg-focused therapies for neurodegenerative and immune-mediated diseases.
$4.57
After-hours close−0.02 (−0.52%)
At close$4.60(−5.45%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.35 | — | — |
| Aug 2026 | −$0.35 | −$0.28 | +19.0% |
| May 2026 | −$0.39 | −$0.32 | +17.9% |
| Mar 2026 | −$0.27 | −$0.34 | −24.8% |
| Nov 2025 | $0.02 | −$0.10 | −600.0% |
The latest year is open to everyone — the 18 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.35 | — | — | $110.0K | — | — |
| Aug 11, 2026 | −$0.35 | −$0.28 | +19.0% | $130.0K | $221.9K | +70.7% |
| May 12, 2026 | −$0.39 | −$0.32 | +17.9% | $150.0K | $300.0K | +100.0% |
| Mar 16, 2026 | −$0.27 | −$0.34 | −24.8% | $2.2M | $4.0M | +78.0% |
| Nov 12, 2025 | $0.02 | −$0.10 | −600.0% | $1.9M | $3.6M | +85.1% |
The latest year is open to everyone — the 18 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 18, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 19, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 29, 2023 | ||||||
| Dec 30, 2022 | ||||||
| Sep 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||